Managers / Q1 2021 · view latest →
Roumell Asset Management, LLC
CIK 0001331693 · 2 WISCONSIN CIR, SUITE 700, CHEVY CHASE, MD, 20815 · 301-656-8500
Summary
Roumell Asset Management, LLC reported $69M in U.S.-listed holdings across 14 positions for Q1 2021.
Its largest position, Allot, represents 17.3% of the portfolio.
Compared with Q4 2020, the fund opened 6 new positions and exited 8.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 72.8% · $50M
- Other · 27.2% · $19M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| QUANTUM CORP | NEW | +901.5K | 901.5K | +$8M | $8M |
| EROS STX GLOBAL CORPORATION | NEW | +1.65M | 1.65M | +$3M | $3M |
| ATENA10 NETWORKS INC | NEW | +166.2K | 166.2K | +$2M | $2M |
| NODKNI HLDGS INC | NEW | +82.1K | 82.1K | +$2M | $2M |
| CLMBWAYSIDE TECHNOLOGY GROUP INC | NEW | +60.2K | 60.2K | +$2M | $2M |
| ARDSARIDIS PHARMACEUTICALS INC | NEW | +222.2K | 222.2K | +$1M | $1M |
| STREAMLINE HEALTH SOLUTIONS | ADDED | +1.10M | 1.89M | +$3M | $4M |
| BCDABIOCARDIA INC | ADDED | +692.1K | 1.26M | +$4M | $5M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ALLOT LTD | SHS | 17.31% | $12M | 749.7K |
| 2 | GSITGSI TECHNOLOGYhistory → | COM | 13.82% | $10M | 1.43M |
| 3 | ENZBENZO BIOCHEM INChistory → | COM | 13.61% | $9M | 2.74M |
| 4 | QUANTUM CORP | COM NEW | 10.86% | $8M | 901.5K |
| 5 | TTITETRA TECHNOLOGIES INC DELhistory → | COM | 8.66% | $6M | 2.49M |
| 6 | BCDABIOCARDIA INChistory → | COM | 7.89% | $5M | 1.26M |
| 7 | STREAMLINE HEALTH SOLUTIONS | COM | 5.61% | $4M | 1.89M |
| 8 | RICEBRAN TECHNOLOGIES | COM NEW | 5.44% | $4M | 3.80M |
| 9 | EROS STX GLOBAL CORPORATION | SHS NEW | 4.32% | $3M | 1.65M |
| 10 | SWCHFSIERRA WIRELESS INChistory → | COM | 3.91% | $3M | 183.1K |
| 11 | ATENA10 NETWORKS INChistory → | COM | 2.31% | $2M | 166.2K |
| 12 | NODKNI HLDGS INChistory → | COM | 2.19% | $2M | 82.1K |
| 13 | CLMBWAYSIDE TECHNOLOGY GROUP INChistory → | COM | 2.19% | $2M | 60.2K |
| 14 | ARDSARIDIS PHARMACEUTICALS INChistory → | COM | 1.90% | $1M | 222.2K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2024 | $53M | 16 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $53M | 17 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $47M | 15 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $50M | 19 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $51M | 22 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $44M | 20 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $40M | 21 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $46M | 21 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $51M | 21 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $62M | 19 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $75M | 21 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $75M | 17 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $86M | 18 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $69M | 14 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $64M | 16 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $50M | 14 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $41M | 20 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $37M | 22 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $44M | 21 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $42M | 14 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $42M | 18 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $41M | 20 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $48M | 22 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.